Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy of different doses of buprenorphine on withdrawal symptoms and psychological outcomes in opioid-dependent patients
IRCT2017071925160N6Phase 4Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Aug 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of buprenorphine in opioid use disorder (OUD), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Reduction in opioid withdrawal symptoms, Reduction in anxiety and 2 more. Started Aug 2017; status: completed.
02
Drugs
buprenorphine
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on IRCT2017071925160N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017071925160N6.